Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Summary of Pro Forma Results (Details)

v3.6.0.2
Acquisitions, Investments, and Licenses - Summary of Pro Forma Results (Details) - Transition Therapeutics, Inc. - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]    
Revenues $ 1,221,661 $ 491,738
Net loss (31,807) (50,660)
Net loss attributable to common shareholders $ (31,807) $ (49,260)